(58 days)
Not Found
No
The document describes the use of dose conversion and reconstruction algorithms and gamma analysis, which are traditional image processing and comparison techniques, not explicitly AI/ML. There is no mention of AI, ML, deep learning, training data, or model performance metrics typically associated with AI/ML devices.
No
The device is a software tool intended to assist in reducing clinical risk in radiotherapy treatments by detecting gross errors and checking the delivered dose; it does not alter treatment delivery, but rather supports decision making and provides treatment assurance.
No
Explanation: The device is described as a software tool intended to assist in reducing the clinical risk in the delivery of radiotherapy treatments and provide an independent means of checking the dose delivered to the patient, serving as an added level of treatment assurance. It compares delivered dose data with planned data, but does not provide diagnostic information about a patient's condition or disease state.
Yes
The device is explicitly described as a "standalone software tool" and a "new standalone software". While it interacts with hardware (linear accelerator and EPID), the device itself is the software component that processes data from that hardware.
Based on the provided information, this device is NOT an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- iViewDose Functionality: iViewDose is a software tool that processes data acquired from an Electronic Portal Imaging Device (EPID) during radiotherapy treatment. It compares this data with treatment planning system data to check the delivered dose. This process involves analyzing radiation passing through the patient or phantom, not analyzing biological samples taken from the patient.
- Intended Use: The intended use is to assist in reducing clinical risk during radiotherapy delivery by detecting gross errors in dose delivery. This is a quality assurance and verification tool for the physical delivery of radiation, not a diagnostic test performed on biological samples.
Therefore, iViewDose falls under the category of a medical device used in radiotherapy, but it does not meet the definition of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
iViewDose is a standalone software tool, available as an optional accessory of the linear accelerator. It is intended to assist in reducing the clinical risk in the delivery of radiotherapy treatments and does not alter the treatment delivery, or impact the clinical workflow.
The software is to be used for the purposes of detecting gross errors during the delivery of radiation therapy. The software acquires data using the iViewGT Electronic Portal Imaging Device at the time of treatment) and subsequently processes it. The processed data is compared with data calculated by the treatment planning system. The comparison is derived from the application of dose conversion and reconstruction algorithms to the EPID data, which is back-projected to a plane normal to a beam (2D) or multiple planes (3D) inside the patient (in vivo) or phantom (pretreatment).
iViewDose is not a treatment planning system, and provides an independent means of checking the dose delivered to the patient.
iViewDose therefore provides an added level of treatment assurance, thus giving clinicians greater confidence especially when complex treatment techniques are employed.
iViewDose is intended to support decision making in relation to the delivery of radiation to defined target volumes performed with Elekta linear accelerators only.
Product codes
IYE
Device Description
This Traditional 510(k) describes a new standalone software to be used with the Elekta range of medical linear accelerators, to further enhance the existing functionality.
The iViewDose program uses iViewGT™ images to reconstruct the dose in 3D in the volume (patient or phantom). The program then uses a gamma analysis to compare the reconstructed dose with the TPS dose in 3D. iViewDose uses a dose reconstruction algorithm to calculate the dose in the patient from the dose delivered to the MV detector panel. The algorithm corrects for scattered radiation from the patient and the MV detector panel. You can use iViewDose in vivo to make an estimate of the delivered dose to a patient. You can also use iViewDose for pre-treatment checks to make an estimate of the delivered dose to a phantom.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Electronic Portal Imaging Device (EPID)
Anatomical Site
anywhere in the body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinicians
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Testing in the form of module, integration and system level verification was performed to evaluate the performance and functionality of the new features against the requirement specification.
Validation of the system under clinically representative conditions has been performed by competent and professionally qualified personnel. Results from verification and validation testing demonstrate that conformance to applicable technical design specification have been met and safety & effectiveness have been achieved.
This testing has shown that iViewDose is safe in use, as it does not provide any direct clinical functionality. Also, the use of iViewDose has been shown to have equivalent clinical efficacy when compared to the predicate devices for which this submission is claiming.
Although no clinical testing has been performed as part of the development, it can be shown that the algorithm at the core of the iViewDose product has been used extensively for a number of years. The data reviewed as part of this evaluation has been obtained from clinical sites. The data is presented in section 11 of this submission.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is often associated with healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the symbol. The logo is black and white.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 11, 2015
Elekta Limited % Mr. Maurice Paine Quality & Regulatory Affairs Engineer Linac House, Fleming Way Crawley, West Sussex RH10 9RR UNITED KINGDOM
Re: K153011
Trade/Device Name: iVIEWDose R1.0 Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: October 9, 2015 Received: October 14, 2015
Dear Mr. Paine:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael D'Hara
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K153011
Device Name
iViewDose R1.0
Indications for Use (Describe)
iViewDose is a standalone software tool, available as an optional accessory of the linear accelerator. It is intended to assist in reducing the clinical risk in the delivery of radiotherapy treatments and does not alter the treatment delivery, or impact the clinical workflow.
The software is to be used for the purposes of detecting gross errors during the delivery of radiation therapy. The software acquires data using the iViewGT Electronic Portal Imaging Device at the time of treatment) and subsequently processes it. The processed data is compared with data calculated by the treatment planning system. The comparison is derived from the application of dose conversion and reconstruction algorithms to the EPID data, which is back-projected to a plane normal to a beam (2D) or multiple planes (3D) inside the patient (in vivo) or phantom (pretreatment).
iViewDose is not a treatment planning system, and provides an independent means of checking the dose delivered to the patient.
iViewDose therefore provides an added level of treatment assurance, thus giving clinicians greater confidence especially when complex treatment techniques are employed.
iViewDose is intended to support decision making in relation to the delivery of radiation to defined target volumes performed with Elekta linear accelerators only.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the Elekta company logo. The logo consists of a circle with a gap in the upper right quadrant. There are five dots of decreasing size along the gap in the circle. To the right of the circle is the company name, ELEKTA, in all caps.
510(k) SUMMARY
Date of preparation of summary: Submitted by:
October 09, 2015 Elekta Limited Linac House, Fleming Way, Crawley, West Sussex RH10 9RR, United Kingdom Telephone: +44 (0) 1293 654284 Fax: +44 (0) 1293 658445
Establishment Registration No.: Contact Name: Trade Name: Common Name: Classification Name:
Product Code: Predicate Devices: 9617016 Mr. Maurice Paine iViewDose R1.0 EPID Dosimetry Medical charged-particle radiation therapy system, 21 CFR 892.5050 IYE DOSIsoft SA, EPIgray (K112723) Math Resolutions LLC, Dosimetry Check Version 4 Release 1 (K132605) Math Resolutions LLC, Dosimetry Check with Exit Dose (K101503)
Product Description:
This Traditional 510(k) describes a new standalone software to be used with the Elekta range of medical linear accelerators, to further enhance the existing functionality.
The iViewDose program uses iViewGT™ images to reconstruct the dose in 3D in the volume (patient or phantom). The program then uses a gamma analysis to compare the reconstructed dose with the TPS dose in 3D. iViewDose uses a dose reconstruction algorithm to calculate the dose in the patient from the dose delivered to the MV detector panel. The algorithm corrects for scattered radiation from the patient and the MV detector panel. You can use iViewDose in vivo to make an estimate of the delivered dose to a patient. You can also use iViewDose for pre-treatment checks to make an estimate of the delivered dose to a phantom.
Indications for Use and Intended Use statement:
The Intended Use for the iViewDose product is as follows:
iViewDose is a standalone software tool, available as an optional accessory of the linear accelerator. It is intended to assist in reducing the clinical risk in the delivery of radiotherapy treatments and does not alter the treatment delivery, or impact the clinical workflow.
The software is to be used for the purposes of detecting gross errors during the delivery of radiation therapy. The software acquires data using the iViewGT Electronic Portal Imaging
4
Device at the time of treatment (or prior to treatment) and subsequently processes it. The processed data is compared with data calculated by the treatment planning system. The comparison is derived from the application of dose conversion and reconstruction algorithms to the EPID data, which is back-projected to a plane normal to a beam (2D) or multiple planes (3D) inside the patient (in vivo) or phantom (pre-treatment).
iViewDose is not a treatment planning system, and provides an independent means of checking the dose delivered to the patient.
iViewDose therefore provides an added level of treatment assurance, thus giving clinicians greater confidence especially when complex treatment techniques are employed.
iViewDose is intended to support decision making in relation to the delivery of radiation to defined target volumes performed with Elekta linear accelerators only.
This software does not alter the existing Indications for Use of the Elekta series of medical linear accelerators, and therefore the existing indications for use statement remains valid:
The Elekta medical linear accelerator system is indicated to be used for image guided stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body when radiation treatment is indicated.
Summary of Technological Characteristics:
The software utilises MV images taken through the iViewGT™ hardware platform, and calculates the dose delivered at a user specified reference plane in 2D, or multiple planes in 3D. The calculated dose is then compared to the planned treatment dose and provides the clinical user with an indication of whether the dose delivered is in accordance with the planning dose. The software uses a back projection algorithm to product the calculated dose.
There has been no change made to the underlying technological characteristics of the linear accelerator device.
The iViewDose accessory consists of software only, and encompasses several third party software components. These third party components have been treated as SOUP in accordance with IEC62304.
The iViewDose product is subject to compliance testing as defined in internationally recognised safety standards. Details of the standards employed in the design are specified in the Standard Data Report in section 9, whilst the verification activities are captured in section 16-11 of this submission.
Substantial Equivalence:
The release of iViewDose R1.0 provides the ability to use EPID images acquired from the iViewGT imaging system mounted to a linear accelerator to reconstruct the dose delivered to the patient or phantom. The software compares the reconstructed dose with the planned dose (from a compatible treatment planning system).
5
Image /page/5/Picture/0 description: The image shows the logo for Elekta. The logo consists of a circle with a break in the upper right quadrant, and a series of dots that decrease in size along the break in the circle. To the right of the circle is the word "ELEKTA" in a sans-serif font.
The following products are identified as Predicate Devices
- 0 Dosimetry Check with exit Dose from Math Resolutions, LLC (K101503)
- 0 Dosimetry Check Version 4 Release 1 from Math Resolutions, LLC (K132605)
- o EPIgray from DOSIsoft SA, (K112723)
Math Resolutions, LLC creates software for use in the radiological sciences. Dosimetry Check has been on the market since 2001.
DOSIsoft was founded in 2002, from a partnership between Gustave Roussy and Institut Curie – two major cancer treatment centres in Europe. EPIgray was launched in 2011 for EPID-based in vivo dosimetry.
The differences in technological characteristics between iViewDose and the predicate devices do not raise questions of safety and effectiveness.
6
| Functionality | iViewDose
R1.0 | EPIgray
(DOSIsoft SA) | Dosimetry
Check
Version 4
Release 1
(Math
Resolutions,
LLC) | Dosimetry
Check with
Exit Dose
(Math
Resolutions,
LLC) |
|-----------------------------------------------------------------------------------------------|---------------------|----------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Control Number | K - - - - - - - - - | K112723 | K132605 | K101503 |
| Independent software | Yes | Yes | Yes | Yes |
| Option for use with Elekta
Radiation Therapy Systems | Yes | Yes | Yes | Yes |
| Pre-treatment images | Yes | Yes | Yes | Yes |
| Treatment images | Yes | Yes | Yes | Yes |
| Algorithm for calculating
reconstructed dose | Yes | Yes | Yes | Yes |
| Compares reconstructed
dose to planning system
dose | Yes | Yes | Yes | Yes |
| Generates a report for the
reviewer to export to file | Yes | Yes | Yes | Yes |
| Results include a %
difference at the dose
reference point | Yes | Yes | Yes | Yes |
| Volume Analysis per
Fraction | Yes | Yes | Yes | Yes |
| Volume Analysis per Beam | Yes | Yes | Yes | Yes |
| Total Dose assessment per
fraction | Yes | Yes | Yes | Yes |
| Total Dose assessment per
treatment | Yes | Yes | Yes | Yes |
| Ability to view a Dose profile | Yes | Yes | Yes | Yes |
| Ability to view EPID images | Yes | Yes | Yes | Unknown |
| Ability to view analysis in
multiple anatomical planes | Yes | Yes | Yes | Yes |
| Analysis points can be single
or multiple (2D or 3D) | Yes | Yes | Yes | Yes |
| Filters by date, by fraction
and by field | Yes | Yes | Yes | Yes |
| User defined Alert Criteria
for out of tolerance analysis | Yes | Yes | Yes | Yes |
| Import Approved Plan data
from Treatment Planning
System | Yes | Yes | Yes | Yes |
| Import portal images
acquired during treatment | Yes | Yes | Yes | Yes |
| Import portal images
acquired during pre-
treatment | Yes | Yes | Yes | Yes |
| Analysis performed
automatically offline | Yes | Yes | Yes | Yes |
| Results statistics available in
the report | Yes | Yes | Yes | Yes |
| Results presented as a
Gamma Analysis | Yes | Yes | Yes | Yes |
| Report may be stored within
Patient Record in MOSAIQ | Yes | Requires
converting to
pdf | Requires
converting to
pdf | Yes |
| Multiple Treatment
Planning Systems | | | | |
| (initially iViewDose is only
validated as being
compatible with Monaco
and Pinnacle) | Yes | Yes | Yes | Yes |
| MOSAIQ Record & Verify
System | Yes | Yes | Yes | Yes |
| Multiple Treatment
techniques
(IMRT and VMAT) | Yes | Yes | Yes | Yes |
| Multiple EPID's | No | Yes | Yes | Yes |
| MV Panel Calibration
required for commissioning | Yes | Yes | Yes | Yes |
| Pre-treatment Check | Yes | Yes | Yes | Yes |
:
.
"
:
7
Image /page/7/Picture/0 description: The image shows the logo for Elekta. The logo consists of a circle with a gap in the upper right quadrant, and a series of dots of decreasing size leading up to the gap. To the right of the circle is the word "ELEKTA" in a sans-serif font.
Elekta Limited, Linac House, Fleming Way, Crawley, West Sussex RH10 9RR UK Tel:+44 (0)1293 544422 Fax:+44 (0)1293 654321 www.elekta.com Registered in England No. 3244454
8
Summary of Non-Clinical Performance Testing:
Testing in the form of module, integration and system level verification was performed to evaluate the performance and functionality of the new features against the requirement specification.
Validation of the system under clinically representative conditions has been performed by competent and professionally qualified personnel. Results from verification and validation testing demonstrate that conformance to applicable technical design specification have been met and safety & effectiveness have been achieved.
This testing has shown that iViewDose is safe in use, as it does not provide any direct clinical functionality. Also, the use of iViewDose has been shown to have equivalent clinical efficacy when compared to the predicate devices for which this submission is claiming.
The system is subject to compliance testing to voluntary consensus safety standards. Details of the standards employed in the design are specified in the Standard Data Report in section 9 which includes but not limited to IEC 62304, IEC 62366, ISO 14971, and IEC61217.
Although no clinical testing has been performed as part of the development, it can be shown that the algorithm at the core of the iViewDose product has been used extensively for a number of years. The data reviewed as part of this evaluation has been obtained from clinical sites. The data is presented in section 11 of this submission.